Indian IT firms have piled up net cash in excess of Rs 20,000 crore
Wipro, Satyam join TCS, Infosys in beating rupee blues.
The Bangalore-based Himalaya Herbal Healthcare has struck strategic alliances with leading retail chains in its main export markets such as the US, Singapore and Malaysia.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
A recent court ruling in the US on allowing the declaratory judgment provision in the US patent law has come as a boost to Indian pharmaceutical companies such as Ranbaxy, Dr Reddy's, Sun Pharma and Lupin.
Given the uncertainty on the US economic outlook, the rising rupee, and the lack of clarity on imposition of fringe benefit tax on stock options, analysts believe the companies may strike a note of caution on FY08 earnings.
In a fresh round of patent battle over the launch of generic drugs in the US market, domestic pharmaceutical majors Orchid, Sun Pharma and Ranbaxy Laboratories have been sued by Cima Labs, Otsuka Pharmaceutical Co and Abbott Laboratories, respectivel
Fortis Healthcare, promoted by the Singh family of Ranbaxy, plans to expand its network to 40 hospitals within three years by either acquiring new facilities or setting up greenfield projects
The turnover of commodity and stocks futures grew at a scorching pace in 2006-07, accounting for 80 per cent of the total turnover of the cash and futures markets.
The US slowdown, service tax on leased and rented premises and imposition of minimum alternate tax are expected to take a toll on the revenue and earnings growth rates of all frontline IT companies in 2007-08.
The appreciation of the rupee, the dividend distribution tax and the hangover of the minimum alternate tax on information technology companies under the Software Technology Parks of India scheme have pulled the prices of IT stocks down.
Beer is gaining more popularity in some of the non-traditional beer markets in North India like Rajasthan, Punjab, Delhi and Uttar Pradesh.
Amgen, the world's largest biotechnology company, has entered India by opening a wholly owned subsidiary Amgen Technology in Mumbai.
Curiously, it will not be far-fetched to state the contrary, that the global stock exchanges follow the Indian markets' cue
The parent companies, however, performed well on the profitability front, posting 30.93 per cent net profit growth compared to 22.6 per cent by their Indian subsidiaries.
Mumbai-based Advanced Enzyme Technologies Ltd, the largest manufacturer of enzymes in the country, will invest Rs 115 crore to set up three biotech production facilities.
With the bidding for the generics business of Merck set to begin from Monday, domestic pharmaceutical companies in the fray, Ranbaxy Laboratories and Dr Reddy's Laboratories, are unlikely to go for an all-out bidding war.
Spectrum Retail Mart, a retail chain of medical stores and fast moving consumer goods, has set up shop in Mumbai with an initial investment of over Rs 90 crore (Rs 900 million).
After being raided by Federal officials, Ranbaxy Laboratories Ltd, India's largest pharmaceutical company, has been taken to court in the US by a consumer health group that supports the sale of low-priced generic medicines.
The Indian company that acquires Merck Generics, the multinational drug maker's generics (non-patented) business, up for sale, will be able to compete against the top global players
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances